American Association for Cancer Research
10780432ccr151031-sup-148458_1_supp_3089629_nt3h39.pptx (36.56 kB)

Supplementary tables from Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Download (36.56 kB)
posted on 2023-03-31, 18:25 authored by Tilak K. Sundaresan, Lecia V. Sequist, John V. Heymach, Gregory J. Riely, Pasi A. Jänne, Walter H. Koch, James P. Sullivan, Douglas B. Fox, Robert Maher, Alona Muzikansky, Andrew Webb, Hai T. Tran, Uma Giri, Martin Fleisher, Helena A. Yu, Wen Wei, Bruce E. Johnson, Thomas A. Barber, John R. Walsh, Jeffrey A. Engelman, Shannon L. Stott, Ravi Kapur, Shyamala Maheswaran, Mehmet Toner, Daniel A. Haber

Supplementary tables S1-S3. Supplementary Table S1: Institutional Tumor Genotyping Strategies. Supplementary Table S2: T790M Genotype by Modality. Supplementary Table S3: EGFR Primary Mutation Detection.


Stand Up To Cancer Dream Team Translational Research

Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research



Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation EGFR TKIs that overcome T790M-associated resistance become available, noninvasive approaches to T790M detection will become critical to guide management.Experimental Design: As part of a multi-institutional Stand-Up-To-Cancer collaboration, we performed an exploratory analysis of 40 patients with EGFR-mutant tumors progressing on EGFR TKI therapy. We compared the T790M genotype from tumor biopsies with analysis of simultaneously collected circulating tumor cells (CTC) and circulating tumor DNA (ctDNA).Results: T790M genotypes were successfully obtained in 30 (75%) tumor biopsies, 28 (70%) CTC samples, and 32 (80%) ctDNA samples. The resistance-associated mutation was detected in 47% to 50% of patients using each of the genotyping assays, with concordance among them ranging from 57% to 74%. Although CTC- and ctDNA-based genotyping were each unsuccessful in 20% to 30% of cases, the two assays together enabled genotyping in all patients with an available blood sample, and they identified the T790M mutation in 14 (35%) patients in whom the concurrent biopsy was negative or indeterminate.Conclusions: Discordant genotypes between tumor biopsy and blood-based analyses may result from technological differences, as well as sampling different tumor cell populations. The use of complementary approaches may provide the most complete assessment of each patient's cancer, which should be validated in predicting response to T790M-targeted inhibitors. Clin Cancer Res; 22(5); 1103–10. ©2015 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager